TY  - JOUR
AU  - Bellido, Virginia
AU  - Martínez, Julia
AU  - Calvo, Fernando
AU  - Villarroel, Aida
AU  - Lecumberri, Edurne
AU  - Moreno, Juan
AU  - Morillas, Carlos
AU  - Rodrigo, Silvia
AU  - Izarra, Aitziber
AU  - Lecube, Albert
PY  - 2022
DO  - 10.1007/s13300-022-01237-9
SN  - 1869-6953
UR  - http://hdl.handle.net/10668/21374
T2  - Diabetes therapy : research, treatment and education of diabetes and related disorders
AB  - Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or...
LA  - en
KW  - Cardiometabolic risk factors
KW  - Dapagliflozin
KW  - Diabetes mellitus
KW  - Diabetic angiopathy
KW  - Sodium-glucose cotransporter 2 inhibitors
KW  - Therapeutic inertia
TI  - Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications.
TY  - research article
VL  - 13
ER  -